Taysha Gene Therapies, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Financial statements are unaudited. Taysha is a clinical-stage AAV gene-therapy company; it has no approved products and has not generated product-sales revenue.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $2.4 million | — | $7.1 million | — |
| Research and development | $19.8 million | $23.5 million | $32.3 million | $61.7 million |
| General and administrative | $6.0 million | $9.9 million | $14.7 million | $21.3 million |
| Net loss | $24.6 million | $34.1 million | $42.2 million | $84.4 million |
| Basic and diluted loss per share | $0.38 | $0.85 | $0.66 | $2.16 |
| Operating cash used | Not separately provided | Not separately provided | $39.0 million | $74.3 million |
Q2 revenue came from Rett-related research and development services under the Astellas agreement, not product sales. Gross margin is not applicable to the disclosed revenue. Six-month operating expenses were $47.0 million, down from $83.0 million; lower R&D and G&A spending reduced the operating loss to $39.9 million from $83.0 million.
At June 30, cash and cash equivalents were $45.1 million, plus $2.6 million of restricted cash. Current assets were $54.1 million and current liabilities $50.6 million. Total liabilities were $118.7 million; stockholders’ deficit was $37.1 million. Term-loan principal was $40.0 million ($38.4 million net carrying value); interest is variable, and principal payments begin after the interest-only period ending August 2024, with maturity in August 2026. Six-month interest expense was $2.8 million, versus $1.4 million a year earlier.
Material changes and developments
- Revenue began under the Astellas collaboration; $7.1 million was recognized in the first half as Rett R&D activities were performed. Deferred revenue at June 30 was $26.5 million, including current and long-term portions.
- Management attributed lower R&D expense to the prior-year strategic reprioritization, reduced headcount, fewer manufacturing and raw-material purchases, and lower preclinical and consulting costs. Rett trial activity partly offset the decline. G&A fell mainly due to lower compensation and consulting costs.
- Operating cash use declined year over year, while investing cash use was $3.9 million, primarily capital spending to close out the in-house manufacturing-facility project. Six-month financing cash flow was less than $0.1 million.
- A $3.5 million Abeona Rett license milestone was recorded as R&D expense and accrued after the first TSHA-102 patient was dosed. Management also disclosed a higher estimated cost to complete Rett R&D activities, with a stated $3.1 million cumulative revenue impact relative to prior estimates.
Outlook, commentary and risks
- Financing and going concern: Management said expected proceeds from an August 2023 private placement would fund planned operations into the third quarter of 2025. The filing nevertheless concludes that substantial doubt about the company’s ability to continue as a going concern exists, reflecting forecast uncertainty and ongoing losses. The placement was agreed after quarter-end and was expected to close by August 16, 2023: approximately $150 million gross for 122.4 million common shares and pre-funded warrants for 44.3 million shares, before fees. Warrant exercise requires stockholder approval; failure to obtain it by the specified deadline can trigger liquidated damages.
- Programs: Taysha is prioritizing TSHA-102 for Rett syndrome and TSHA-120 for GAN; substantially all other R&D programs have been paused or deprioritized. The first adult Rett participant had no treatment-emergent serious adverse events reported through six weeks, and the data monitoring committee cleared dosing of the next patient. Initial efficacy observations disclosed in August are from one patient and are preliminary. FDA clearance for a pediatric TSHA-102 IND was also reported in August.
- For TSHA-120, the FDA identified MFM32 as an acceptable endpoint but recommended additional patients in a randomized, double-blind, placebo-controlled study to support a BLA. The FDA’s review of existing safety data depends on product comparability. In July 2023, the company reported FDA feedback that its analytical data supported comparability and pivotal-lot release for planned clinical studies; a future regulatory path is not assured.
- Key risks: Taysha reported a July 2023 notice from Hannah’s Hope Foundation alleging breach of the TSHA-120 license; the company disputes the allegation, but resolution is uncertain. Nasdaq had notified the company of bid-price noncompliance (deadline October 23, 2023) and minimum market-value noncompliance (deadline January 30, 2024); failure to regain compliance could lead to delisting. The company also faces clinical, regulatory, manufacturing, financing, dilution and license-compliance risks. No material legal proceedings were reported, apart from the disclosed license dispute.
Important facts for investors to verify
- Whether the August private placement closed on the stated terms, net proceeds after fees, stockholder approval for warrant exercise, and resulting fully diluted share count.
- Actual cash burn, spending against the projected runway, and whether management’s going-concern assessment changes.
- Subsequent TSHA-102 safety and efficacy data, trial enrollment and pediatric development; treat the first-patient observations as preliminary.
- FDA feedback and the clinical/regulatory plan for TSHA-120, including study design, comparability and safety-database requirements.
- Status and consequences of the Hannah’s Hope Foundation license dispute and Nasdaq listing deficiencies.
- Term-loan interest costs, repayment terms, and the company’s ability to meet future license, lease and clinical commitments.